Haytham Aljoudi, MD
Cardiovascular Disease (Cardiology) · Stockton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 7
- Since medical school
- 25 years
- Graduated 2001
Offices
7 locations · Adventist Health Physicians Network · Lodi Memorial Hospital Association Inc
Hospitals listed: Adventist Health Lodi Memorial · Dameron Hospital · Stanford Health Care · St Joseph'S Medical Center of Stockton. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Aljoudi’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C150276 · Current
Licensed to practise in California · since 2017 · expires 2028-11-30 · University of Jordan Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Washington MD.MD.00047415Physician And Surgeon License · since 2006 · expires 2007-11-28ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Cardiology
- American Board of Internal Medicine - Interventional Cardiology
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health Lodi MemorialLodi, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.222, Oct 2024 – Sep 2025
- Dameron HospitalStockton, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency departmentPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 2 of 5 · 58% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — MRSA Bacteremia: 18.373, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- St Joseph'S Medical Center of StocktonStockton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.08, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.34, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Adventist Health Lodi Memorial
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 6 the same, 0 worse of 6 measures. Readmissions: 1 better, 3 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.222 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.16 to 2.22) · 678 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.59 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 203.28 (143.15 to 263.4) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 43 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 334 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 570 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 1,823 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.02 to 0.45) · 4,072 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.08 to 0.49) · 4,094 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.18 (0.83 to 5.53) · 476 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.34) · 81 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.8 to 4.13) · 448 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.29 (0 to 17.86) · 79 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 78 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.18 to 3.16) · 142 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.74 (0 to 1.53) · 3,347 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.368 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.655 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.506 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 27 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 450 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 47.3 · 381 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.2 · 604 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.1 · 661 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.9 · 188 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.6 (8.9 to 15.2) · 932 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 449 cases | No different | Jan 2024 – Dec 2024 |
What patients said (438 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Dameron Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 0 better, 8 the same, 0 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| MRSA BacteremiaInfections | 18.373 | Worse | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.46 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.1 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.5 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.5 · 75 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.5 · 121 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.8 · 41 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.6 · 730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,121 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.09 to 0.52) · 1,225 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.06 (0.59 to 5.54) · 371 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.34) · 116 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.41 (0.76 to 4.05) · 363 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.35 (0.5 to 18.2) · 123 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.94 (0.72 to 9.16) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 74 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.36 (0 to 1.37) · 1,066 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.678 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 118 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 144 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 41.3 · 92 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 5.5 · 89 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 22.9 · 118 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 178 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.2 · 44 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 78 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.2) · 386 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.5) · 261 cases | No different | Jan 2024 – Dec 2024 |
What patients said (385 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 1 |
| Communication about medicines | 1 |
| Discharge information | 1 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 66% |
| Staff "always" explained | 49% |
| Yes, staff "did" give patients this information | 77% |
| Yes, staff "did" give patients information about help after discharge | 72% |
| Doctors "always" explained things so they could understand | 62% |
| Doctors "always" listened carefully | 63% |
| Doctors "always" treated them with courtesy and respect | 74% |
| Patients who gave a rating of "9" or "10" (high) | 55% |
| Staff "always" explained new medications | 61% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 58% |
| Staff "always" explained possible side effects | 37% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for St Joseph'S Medical Center of Stockton
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.08 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.34 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.51 (0.54 to 2.47) · 1,424 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.78 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.22 (98.08 to 180.36) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 127 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.9 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.2 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.4 · 405 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9 · 337 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,812 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.09 to 0.49) · 6,528 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,304 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.48 (1.49 to 5.48) · 1,467 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.27 (0 to 2.79) · 464 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.81 to 3.64) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.16 (1.3 to 13.02) · 455 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (1.5 to 8.93) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.24 (0.78 to 3.71) · 262 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.03 (0.53 to 1.53) · 6,521 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.537 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.486 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.646 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 484 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 878 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.2 · 265 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17.1 · 493 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 407 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 615 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.1 · 184 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 164 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 290 cases | No different | Jan 2024 – Dec 2024 |
What patients said (541 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$416,320
Medicare paid this office $416,320 for 1,742 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 476 | $69,493 | $97 |
| Critical care, first 30-74 minutes | 138 | $53,456 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 134 | $24,053 | $98 |
| Long return visit (40+ min) | 121 | $20,052 | $142 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 132 | $20,047 | $150 |
See all 43 services
| Return visit (30+ min) | 476 | $69,493 | $97 |
| Critical care, first 30-74 minutes | 138 | $53,456 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 134 | $24,053 | $98 |
| Long return visit (40+ min) | 121 | $20,052 | $142 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 132 | $20,047 | $150 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 51 | $18,726 | $360 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 322 | $18,158 | $55 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 19 | $9,845 | $394 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $8,885 | $141 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 26 | $8,808 | $59 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 50 | $8,808 | $176 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 51 | $7,783 | $75 |
| New patient visit (45+ min) | 67 | $7,069 | $106 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 882 | $7,061 | $7 |
| Ultrasound of both sides of head and neck blood flow | 40 | $6,248 | $156 |
| New patient visit (60+ min) | 30 | $5,325 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $4,389 | $66 |
| Insertion of permanent leadless pacemaker using imaging guidance | 11 | $3,879 | $353 |
| Ultrasound of leg arteries or artery grafts | 15 | $3,214 | $214 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 52 | $2,838 | $54 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 21 | $2,737 | $130 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $2,704 | $108 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 40 | $2,515 | $63 |
| Programming of dual lead pacemaker system | 29 | $2,302 | $62 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 361 | $2,300 | $5 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 205 | $2,250 | $10 |
| Ultrasound of leg arteries at rest and after exercise | 12 | $1,628 | $136 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 33 | $1,524 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 44 | $1,495 | $18 |
| Return visit (30+ min) | 14 | $1,376 | $81 |
| Injection, regadenoson, 0.1 mg | 44 | $1,034 | None |
| Review by radiologist of both arms or legs arteries image | 13 | $967 | $74 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 93 | $958 | $10 |
| Anticoagulant management of patient taking warfarin | 14 | $843 | $9 |
| Programming of single lead pacemaker system | 14 | $765 | $55 |
| Review by radiologist of abdominal aorta image | 14 | $750 | $54 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 35 | $716 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 40 | $463 | $12 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 11 | $452 | $27 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 24 | $422 | $18 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 27 | $387 | $14 |
| Ultrasound of heart, follow-up | 12 | $268 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 44 | $263 | $6 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 15 | More than 39% of doctors who do this |
| Leg revascularization (restoring blood flow) | 1-10 | None |
| Pacemaker insertion or repair | 20 | More than 71% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Insertion of permanent leadless pacemaker using imaging guidance | – | – | – | – | 11 | 11 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,742 Original Medicare patients in 2024. Average age 76 · Under 65 9% · 85 and older 21% · Women 53% · Also on Medicaid 39% · Health risk score 1.91. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Diabetes 45% · Coronary heart disease 41% · Chronic kidney disease 40% · Heart failure 38% · Atrial fibrillation 34% · COPD 27% · Depression 24% · Stroke 17% · Cancer 14% · Dementia 13%.
The office billed $1,709,237, Medicare allowed $541,857 and paid $416,320; for 5,484 services of 113 kinds; $1,034 of it was for drugs given in the office and $415,286 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,742 | 5,484 | 76 | 1.91 | $1,709,237 | $416,320 |
| 2023 | 881 | 4,167 | 75 | 1.78 | $1,468,373 | $361,217 |
| 2022 | 615 | 2,640 | 74 | 1.88 | $981,866 | $234,581 |
| 2021 | 595 | 2,779 | 74 | 2.13 | $1,049,292 | $249,996 |
| 2020 | 611 | 2,457 | 73 | 2.17 | $978,488 | $221,046 |
| 2019 | 633 | 2,529 | 73 | 2.32 | $1,034,958 | $229,190 |
| 2018 | 509 | 2,032 | 73 | 1.98 | $796,526 | $178,144 |
| 2017 | 172 | 510 | 74 | 1.46 | $133,666 | $35,282 |
| 2016 | 1,219 | 2,270 | 68 | 2.19 | $199,060 | $66,576 |
| 2015 | 928 | 1,680 | 67 | 1.84 | $161,538 | $56,652 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 37 services
| Return visit (30+ min) | 439 | $69,229 | $95 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 90 | $32,344 | $359 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 127 | $28,917 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 167 | $25,748 | $151 |
| Critical care, first 30-74 minutes | 43 | $18,352 | $168 |
| New patient visit (45+ min) | 135 | $16,069 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 102 | $14,927 | $138 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 90 | $13,719 | $76 |
| Injection, regadenoson, 0.1 mg | 79 | $13,370 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 226 | $12,951 | $54 |
| Long return visit (40+ min) | 77 | $12,236 | $133 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 23 | $11,065 | $395 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 53 | $9,023 | $170 |
| Ultrasound of both sides of head and neck blood flow | 47 | $7,530 | $160 |
| New patient visit (60+ min) | 38 | $6,136 | $161 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 400 | $5,388 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 90 | $4,582 | $51 |
| Insertion of permanent leadless pacemaker using imaging guidance | 11 | $3,630 | $330 |
| Ultrasound of leg arteries or artery grafts | 12 | $2,446 | $204 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 19 | $1,798 | $29 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 11 | $1,641 | $149 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 25 | $1,584 | $61 |
| Programming of dual lead pacemaker system | 20 | $1,506 | $63 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 18 | $1,063 | $17 |
| Anticoagulant management of patient taking warfarin | 17 | $1,024 | $9 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 94 | $988 | $10 |
| Review by radiologist of both arms or legs arteries image | 11 | $792 | $72 |
| Programming of single lead pacemaker system | 11 | $738 | $53 |
| Review by radiologist of abdominal aorta image | 12 | $624 | $52 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 28 | $610 | $16 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 22 | $594 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 103 | $537 | $5 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 25 | $441 | $17 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 16 | $324 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 25 | $290 | $11 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 11 | $195 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 18 | $117 | $6 |
2022: 30 services
| Return visit (30+ min) | 261 | $35,486 | $90 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 67 | $25,846 | $386 |
| Critical care, first 30-74 minutes | 31 | $17,862 | $177 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 87 | $14,089 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 75 | $13,998 | $83 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 67 | $11,747 | $88 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 175 | $10,624 | $57 |
| Long return visit (40+ min) | 63 | $10,269 | $135 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $10,155 | $161 |
| Injection, regadenoson, 0.1 mg | 52 | $10,093 | None |
| New patient visit (45+ min) | 64 | $8,258 | $129 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 12 | $6,286 | $419 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 31 | $5,972 | $193 |
| New patient visit (60+ min) | 31 | $5,488 | $177 |
| Ultrasound of both sides of head and neck blood flow | 32 | $4,966 | $155 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 66 | $3,489 | $53 |
| Ultrasound of leg arteries or artery grafts | 16 | $3,275 | $205 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 246 | $3,117 | $11 |
| Short return visit (20+ min) | 29 | $1,535 | $53 |
| Programming of dual lead pacemaker system | 16 | $1,125 | $66 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 16 | $965 | $22 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 16 | $891 | $20 |
| Review by radiologist of abdominal aorta image | 13 | $768 | $55 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 60 | $648 | $10 |
| Anticoagulant management of patient taking warfarin | 13 | $519 | $9 |
| Ultrasound of heart, follow-up | 14 | $332 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 13 | $324 | $17 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 12 | $323 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 14 | $73 | $5 |
| Infusion, normal saline solution, 250 cc | 45 | $24 | None |
2021: 32 services
| Return visit (30+ min) | 231 | $36,512 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 64 | $25,737 | $402 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 108 | $18,713 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 76 | $17,146 | $84 |
| Critical care, first 30-74 minutes | 31 | $14,601 | $178 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 229 | $13,386 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 78 | $13,253 | $162 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 63 | $11,021 | $89 |
| Injection, regadenoson, 0.1 mg | 53 | $10,032 | None |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 43 | $8,390 | $191 |
| Long return visit (40+ min) | 56 | $8,289 | $138 |
| Short return visit (20+ min) | 115 | $7,344 | $55 |
| Ultrasound of both sides of head and neck blood flow | 44 | $7,336 | $167 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 14 | $6,697 | $419 |
| New patient visit (45+ min) | 35 | $4,585 | $131 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 62 | $3,350 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 231 | $3,337 | $12 |
| Ultrasound of leg arteries or artery grafts | 16 | $3,215 | $201 |
| New patient visit (60+ min) | 14 | $2,080 | $149 |
| Ultrasound of leg arteries at rest and after exercise | 14 | $1,978 | $141 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 12 | $1,879 | $157 |
| Programming of dual lead pacemaker system | 16 | $1,190 | $66 |
| Review by radiologist of both arms or legs arteries image | 12 | $916 | $76 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 67 | $743 | $10 |
| Review by radiologist of abdominal aorta image | 12 | $662 | $55 |
| Ultrasound of heart, follow-up | 20 | $418 | $20 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 11 | $246 | $22 |
| Ultrasonic guidance for blood vessel access | 11 | $147 | $11 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 19 | $119 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 21 | $57 | $2 |
| Infusion, normal saline solution, 250 cc | 63 | $35 | None |
| Injection, aminophyllin, up to 250 mg | 12 | $24 | None |
2020: 30 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 99 | $20,155 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $16,875 | $164 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 265 | $16,405 | $59 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 41 | $16,117 | $393 |
| Return visit (30+ min) | 126 | $14,822 | $81 |
| Critical care, first 30-74 minutes | 31 | $14,786 | $185 |
| Short return visit (20+ min) | 180 | $12,797 | $52 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 70 | $11,283 | $157 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 18 | $10,013 | $401 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 49 | $9,593 | $188 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 41 | $7,371 | $90 |
| Injection, regadenoson, 0.1 mg | 31 | $5,845 | None |
| Long return visit (40+ min) | 37 | $4,813 | $120 |
| New patient visit (45+ min) | 33 | $3,980 | $121 |
| Ultrasound of leg arteries or artery grafts | 14 | $2,956 | $211 |
| New patient visit (60+ min) | 18 | $2,860 | $159 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 178 | $2,600 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 41 | $2,148 | $52 |
| Ultrasound of both sides of head and neck blood flow | 12 | $1,927 | $161 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 15 | $1,887 | $126 |
| Ultrasound of leg arteries at rest and after exercise | 12 | $1,628 | $136 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 21 | $1,272 | $61 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | $1,156 | $68 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 75 | $894 | $10 |
| Review by radiologist of abdominal aorta image | 11 | $747 | $57 |
| Ultrasound of heart, follow-up | 13 | $261 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 17 | $200 | $12 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 13 | $74 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 15 | $38 | $3 |
| Infusion, normal saline solution, 250 cc | 38 | $19 | None |
2019: 28 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 109 | $21,377 | $84 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 295 | $18,330 | $59 |
| Return visit (30+ min) | 144 | $17,548 | $80 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 41 | $16,603 | $405 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 90 | $15,287 | $159 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 75 | $15,076 | $201 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 74 | $12,744 | $170 |
| Critical care, first 30-74 minutes | 35 | $10,190 | $176 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 20 | $10,105 | $421 |
| Short return visit (20+ min) | 141 | $10,009 | $56 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 41 | $7,142 | $87 |
| Long return visit (40+ min) | 48 | $6,062 | $114 |
| Injection, regadenoson, 0.1 mg | 33 | $6,031 | None |
| New patient visit (60+ min) | 33 | $5,067 | $154 |
| New patient visit (45+ min) | 43 | $4,896 | $114 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 212 | $3,521 | $13 |
| Ultrasound of both sides of head and neck blood flow | 19 | $3,409 | $170 |
| Initial hospital observation care per day, typically 70 minutes | 18 | $2,556 | $142 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 41 | $2,133 | $52 |
| Ultrasound of leg arteries at rest and after exercise | 15 | $2,099 | $140 |
| Review by radiologist of abdominal aorta and both leg arteries image | 19 | $1,334 | $70 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 20 | $1,293 | $65 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 102 | $1,104 | $10 |
| Ultrasound of heart, follow-up | 22 | $484 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 17 | $206 | $12 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 21 | $132 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 24 | $68 | $3 |
| Infusion, normal saline solution, 250 cc | 41 | $20 | None |
2018: 27 services
| Return visit (30+ min) | 202 | $28,208 | $75 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 92 | $15,992 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 86 | $14,870 | $162 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 62 | $14,118 | $228 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 84 | $10,141 | $118 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 165 | $10,013 | $58 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 50 | $9,884 | $194 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 14 | $6,238 | $446 |
| New patient visit (45+ min) | 59 | $6,193 | $105 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 30 | $5,227 | $87 |
| Critical care, first 30-74 minutes | 17 | $4,465 | $179 |
| New patient visit (60+ min) | 35 | $4,150 | $119 |
| Injection, regadenoson, 0.1 mg | 22 | $3,901 | None |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 11 | $2,420 | $220 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 132 | $2,119 | $14 |
| Initial hospital observation care per day, typically 70 minutes | 13 | $1,838 | $141 |
| Ultrasound of both sides of head and neck blood flow | 20 | $1,588 | $79 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 30 | $1,566 | $52 |
| Long return visit (40+ min) | 12 | $1,259 | $105 |
| Review by radiologist of abdominal aorta and both leg arteries image | 15 | $1,057 | $70 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $582 | $53 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 32 | $478 | $15 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 44 | $474 | $10 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 32 | $331 | $10 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 60 | $306 | $5 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 13 | $146 | $11 |
| Infusion, normal saline solution, 250 cc | 30 | $15 | None |
2017: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $4,315 | $85 |
| New patient visit (45+ min) | 36 | $4,011 | $111 |
| Return visit (30+ min) | 47 | $3,900 | $71 |
| New patient visit (60+ min) | 20 | $2,651 | $133 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 11 | $2,631 | $219 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 39 | $2,601 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,298 | $164 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 29 | $1,876 | $65 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 26 | $1,359 | $50 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 29 | $527 | $18 |
| Ultrasound of both sides of head and neck blood flow | 11 | $496 | $45 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 27 | $370 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 29 | $352 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 47 | $345 | $7 |
2016: 11 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 417 | $19,754 | $46 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 35 | $8,809 | $252 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 824 | $7,875 | $6 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 81 | $7,281 | $55 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 45 | $4,735 | $105 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 76 | $4,164 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,381 | $149 |
| Short return visit (20+ min) | 41 | $1,745 | $34 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 70 | $1,103 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 70 | $738 | $11 |
| Ultrasound of heart, follow-up | 19 | $366 | $18 |
2015: 11 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 334 | $16,362 | $48 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 139 | $12,750 | $55 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 35 | $8,700 | $249 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 540 | $4,667 | $6 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 56 | $3,411 | $61 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 49 | $2,013 | $30 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,129 | $94 |
| Short return visit (20+ min) | 25 | $1,129 | $39 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 58 | $1,013 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 56 | $636 | $11 |
| Ultrasound of heart, follow-up | 14 | $278 | $20 |
Medicaid work
$93,935 in 2024
Medicaid paid $93,935 for 2,994 billed services this clinician did in 2024, up to 201 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 412 | $42,613 |
| Return visit (30+ min) | 500 | $18,443 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1,309 | $14,682 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 200 | $5,580 |
| Face-to-face behavioral counseling for obesity, 15 minutes | 186 | $4,224 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 249 | $3,886 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 42 | $1,533 |
| Long return visit (40+ min) | 25 | $1,196 |
| Interrogation device evaluation(s), (remote) up to 30 days; subcutaneous cardiac rhythm monitor system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional | 32 | $905 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | 14 | $685 |
| Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes | 13 | $188 |
| Medication list documented in medical record (COA) | 12 | $0 |
| 2024 | 2,994 | 12 | 201 | $93,935 |
| 2023 | 2,190 | 12 | 69 | $131,107 |
| 2022 | 933 | 6 | 46 | $68,101 |
| 2021 | 1,574 | 8 | 59 | $105,258 |
| 2020 | 1,442 | 8 | 56 | $96,369 |
| 2019 | 1,297 | 10 | 63 | $86,641 |
| 2018 | 982 | 10 | 43 | $70,343 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 444 | $51,517 |
| Return visit (30+ min) | 682 | $24,424 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 52 | $14,587 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 556 | $14,359 |
| New patient visit (45+ min) | 145 | $10,696 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 164 | $5,586 |
| CARDIOVASCULAR STRESS TEST | 25 | $3,017 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 12 | $2,567 |
| 1ST HOSP IP/OBS HIGH 75 | 31 | $2,469 |
| Face-to-face behavioral counseling for obesity, 15 minutes | 30 | $775 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | 14 | $607 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 35 | $505 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 339 | $42,024 |
| Return visit (30+ min) | 287 | $11,917 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 250 | $7,538 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 12 | $3,690 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 31 | $1,608 |
| New patient visit (45+ min) | 14 | $1,324 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 505 | $56,974 |
| Return visit (30+ min) | 420 | $20,713 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 373 | $11,673 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 13 | $4,097 |
| Short return visit (20+ min) | 135 | $4,015 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 74 | $3,989 |
| 1ST HOSP IP/OBS HIGH 75 | 41 | $3,636 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | 13 | $162 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 482 | $52,598 |
| Return visit (30+ min) | 229 | $11,141 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 274 | $9,487 |
| Short return visit (20+ min) | 299 | $8,732 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 26 | $6,765 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 91 | $3,680 |
| 1ST HOSP IP/OBS HIGH 75 | 29 | $2,624 |
| CARDIOVASCULAR STRESS TEST | 12 | $1,341 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 508 | $51,536 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 287 | $9,461 |
| Return visit (30+ min) | 195 | $9,300 |
| Short return visit (20+ min) | 159 | $5,046 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 16 | $4,419 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 82 | $2,911 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 12 | $2,672 |
| CARDIOVASCULAR STRESS TEST | 12 | $1,007 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | 14 | $234 |
| Infusion, normal saline solution, 250 cc | 12 | $54 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 353 | $33,626 |
| Return visit (30+ min) | 239 | $13,510 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 57 | $9,973 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 121 | $4,561 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 30 | $3,663 |
| OFFICE/OP CONSLTJ NEW/EST PT HIGH MDM 55 MINUTES | 14 | $2,146 |
| CARDIOVASCULAR STRESS TEST | 44 | $1,098 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 67 | $929 |
| CARDIOVASCULAR STRESS TEST | 44 | $835 |
| Hospital outpatient clinic visit for assessment and management of a patient | 13 | $0 |
Drugs they prescribed that Part D paid
$1,011,653
Pharmacies billed $1,011,653 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 4,182) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
3,115 generic and 1,067 brand-name prescriptions · $1,011,653 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 234 | $266,358 | $1,138 |
| Xarelto | 285 | $253,850 | $891 |
| Jardiance | 231 | $198,883 | $861 |
| Entresto | 122 | $137,385 | $1,126 |
| Brilinta | 32 | $26,385 | $825 |
See all 40 drugs
| Eliquis | 234 | $266,358 | $1,138 |
| Xarelto | 285 | $253,850 | $891 |
| Jardiance | 231 | $198,883 | $861 |
| Entresto | 122 | $137,385 | $1,126 |
| Brilinta | 32 | $26,385 | $825 |
| Repatha Sureclick | 13 | $19,513 | $1,501 |
| Farxiga | 13 | $15,898 | $1,223 |
| Metoprolol | 498 | $7,718 | $15 |
| Vascepa | 15 | $5,186 | $346 |
| Amiodarone | 56 | $2,951 | $53 |
| Clopidogrel | 273 | $2,935 | $11 |
| Atorvastatin | 294 | $2,837 | $10 |
| Pantoprazole | 38 | $2,642 | $70 |
| Midodrine | 18 | $1,981 | $110 |
| Losartan | 201 | $1,770 | $9 |
| Diltiazem 24hr Er (Cd) | 77 | $1,563 | $20 |
| Lisinopril | 188 | $1,529 | $8 |
| Rosuvastatin | 81 | $1,350 | $17 |
| Metoprolol | 171 | $1,264 | $7 |
| Carvedilol | 138 | $1,257 | $9 |
| Amlodipine Besylate | 234 | $1,211 | $5 |
| Diltiazem 24hr Er | 15 | $1,158 | $77 |
| Furosemide | 220 | $1,135 | $5 |
| Flecainide Acetate | 24 | $1,118 | $47 |
| Cilostazol | 40 | $1,043 | $26 |
| Digoxin | 45 | $899 | $20 |
| Ezetimibe | 23 | $650 | $28 |
| Omeprazole | 18 | $479 | $27 |
| Potassium Chloride | 35 | $474 | $14 |
| Hydralazine | 40 | $449 | $11 |
| Klor-Con 10 | 14 | $304 | $22 |
| Warfarin | 54 | $267 | $5 |
| Isosorbide Mononitrate Er | 27 | $258 | $10 |
| Spironolactone | 37 | $243 | $7 |
| Nitroglycerin | 16 | $239 | $15 |
| Hydrochlorothiazide | 44 | $232 | $5 |
| Simvastatin | 21 | $203 | $10 |
| Diltiazem 24hr Er (Xr) | 13 | $116 | $9 |
| Clonidine | 17 | $112 | $7 |
| Atenolol | 15 | $57 | $4 |
Year by year
| 2024 | 4,182 | 709 | 0% (0) | 26% | $1,011,653 |
| 2023 | 2,840 | 538 | 0% (0) | 23% | $630,933 |
| 2022 | 1,918 | 371 | 0% (0) | 20% | $316,572 |
| 2021 | 1,575 | 276 | None | 22% | $204,905 |
| 2020 | 1,414 | 268 | 0% (0) | 19% | $151,691 |
| 2019 | 1,205 | 211 | None | 25% | $133,837 |
| 2018 | 685 | 133 | 0% (0) | 21% | $56,806 |
| 2017 | 399 | 71 | 0% (0) | 22% | $23,724 |
| 2016 | 418 | 49 | 0% (0) | 27% | $27,187 |
| 2015 | 58 | 15 | 0% (0) | None | $1,074 |
| 2014 | 51 | None | 0% (0) | None | $3,008 |
| 2013 | 35 | None | None | None | $1,181 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 36 drugs
| Xarelto | 211 | $194,644 | $922 |
| Eliquis | 139 | $138,614 | $997 |
| Entresto | 80 | $99,033 | $1,238 |
| Jardiance | 93 | $77,123 | $829 |
| Brilinta | 41 | $27,392 | $668 |
| Repatha Sureclick | 11 | $14,442 | $1,313 |
| Metoprolol | 330 | $7,700 | $23 |
| Diltiazem 24hr Er (Cd) | 69 | $4,297 | $62 |
| Atorvastatin | 182 | $3,197 | $18 |
| Losartan | 179 | $2,640 | $15 |
| Clopidogrel | 155 | $2,596 | $17 |
| Amiodarone | 28 | $2,211 | $79 |
| Amlodipine Besylate | 163 | $1,900 | $12 |
| Lisinopril | 141 | $1,698 | $12 |
| Furosemide | 158 | $1,540 | $10 |
| Carvedilol | 104 | $1,538 | $15 |
| Rosuvastatin | 51 | $1,335 | $26 |
| Pantoprazole | 32 | $1,335 | $42 |
| Metoprolol | 95 | $1,160 | $12 |
| Digoxin | 27 | $1,115 | $41 |
| Potassium Chloride | 28 | $1,046 | $37 |
| Nifedipine Er | 15 | $885 | $59 |
| Cilostazol | 33 | $772 | $23 |
| Flecainide Acetate | 24 | $643 | $27 |
| Bumetanide | 11 | $619 | $56 |
| Ezetimibe | 30 | $545 | $18 |
| Hydralazine | 28 | $519 | $19 |
| Gabapentin | 14 | $373 | $27 |
| Nitroglycerin | 21 | $362 | $17 |
| Warfarin | 30 | $337 | $11 |
| Omeprazole | 24 | $336 | $14 |
| Isosorbide Mononitrate Er | 15 | $274 | $18 |
| Spironolactone | 38 | $221 | $6 |
| Ramipril | 14 | $216 | $15 |
| Pravastatin | 20 | $210 | $11 |
| Hydrochlorothiazide | 13 | $72 | $6 |
2022: 33 drugs
| Xarelto | 141 | $120,166 | $852 |
| Eliquis | 69 | $70,613 | $1,023 |
| Entresto | 29 | $34,063 | $1,175 |
| Brilinta | 29 | $23,333 | $805 |
| Jardiance | 12 | $11,754 | $979 |
| Multaq | 11 | $10,224 | $929 |
| Vascepa | 14 | $6,125 | $438 |
| Metoprolol | 229 | $4,354 | $19 |
| Diltiazem 24hr Er (Cd) | 36 | $3,039 | $84 |
| Atorvastatin | 171 | $2,235 | $13 |
| Rosuvastatin | 45 | $1,697 | $38 |
| Clopidogrel | 121 | $1,534 | $13 |
| Furosemide | 107 | $1,493 | $14 |
| Amlodipine Besylate | 134 | $997 | $7 |
| Digoxin | 33 | $960 | $29 |
| Carvedilol | 69 | $958 | $14 |
| Losartan | 122 | $948 | $8 |
| Amiodarone | 28 | $825 | $29 |
| Ezetimibe | 16 | $810 | $51 |
| Metolazone | 12 | $805 | $67 |
| Flecainide Acetate | 20 | $759 | $38 |
| Potassium Chloride | 17 | $737 | $43 |
| Metoprolol | 72 | $599 | $8 |
| Bumetanide | 21 | $528 | $25 |
| Lisinopril | 89 | $450 | $5 |
| Losartan-Hydrochlorothiazide | 11 | $314 | $29 |
| Pantoprazole | 21 | $309 | $15 |
| Ramipril | 14 | $270 | $19 |
| Nitroglycerin | 11 | $263 | $24 |
| Hydralazine | 18 | $230 | $13 |
| Warfarin | 14 | $192 | $14 |
| Spironolactone | 16 | $129 | $8 |
| Pravastatin | 12 | $15 | $1 |
2021: 23 drugs
| Xarelto | 149 | $101,191 | $679 |
| Eliquis | 56 | $38,382 | $685 |
| Entresto | 18 | $18,760 | $1,042 |
| Brilinta | 25 | $16,917 | $677 |
| Metoprolol | 169 | $4,194 | $25 |
| Diltiazem 24hr Er (Cd) | 50 | $2,596 | $52 |
| Atorvastatin | 120 | $1,680 | $14 |
| Clopidogrel | 107 | $1,326 | $12 |
| Flecainide Acetate | 11 | $1,278 | $116 |
| Digoxin | 33 | $1,066 | $32 |
| Rosuvastatin | 26 | $1,013 | $39 |
| Potassium Chloride | 20 | $965 | $48 |
| Amlodipine Besylate | 140 | $872 | $6 |
| Losartan | 81 | $818 | $10 |
| Amiodarone | 27 | $755 | $28 |
| Carvedilol | 55 | $754 | $14 |
| Furosemide | 99 | $684 | $7 |
| Lisinopril | 112 | $673 | $6 |
| Metoprolol | 80 | $485 | $6 |
| Nitroglycerin | 13 | $417 | $32 |
| Pantoprazole | 23 | $275 | $12 |
| Hydrochlorothiazide | 25 | $126 | $5 |
| Spironolactone | 13 | $124 | $10 |
2020: 20 drugs
| Xarelto | 114 | $67,390 | $591 |
| Eliquis | 38 | $30,251 | $796 |
| Brilinta | 23 | $13,307 | $579 |
| Metoprolol | 196 | $4,273 | $22 |
| Diltiazem 24hr Er (Cd) | 47 | $1,981 | $42 |
| Clopidogrel | 115 | $1,334 | $12 |
| Atorvastatin | 83 | $1,247 | $15 |
| Potassium Chloride | 27 | $937 | $35 |
| Amiodarone | 35 | $913 | $26 |
| Lisinopril | 138 | $888 | $6 |
| Losartan | 46 | $720 | $16 |
| Amlodipine Besylate | 149 | $695 | $5 |
| Metoprolol | 70 | $610 | $9 |
| Digoxin | 28 | $570 | $20 |
| Carvedilol | 38 | $565 | $15 |
| Furosemide | 67 | $519 | $8 |
| Nitroglycerin | 15 | $341 | $23 |
| Isosorbide Mononitrate Er | 12 | $225 | $19 |
| Benazepril | 15 | $201 | $13 |
| Hydrochlorothiazide | 20 | $160 | $8 |
2019: 19 drugs
| Xarelto | 85 | $50,480 | $594 |
| Eliquis | 77 | $28,915 | $376 |
| Brilinta | 60 | $25,905 | $432 |
| Metoprolol | 156 | $4,381 | $28 |
| Diltiazem 24hr Er (Cd) | 25 | $1,896 | $76 |
| Lisinopril | 121 | $838 | $7 |
| Potassium Chloride | 27 | $832 | $31 |
| Clopidogrel | 77 | $807 | $10 |
| Atorvastatin | 57 | $790 | $14 |
| Amlodipine Besylate | 124 | $683 | $6 |
| Losartan | 52 | $535 | $10 |
| Rosuvastatin | 11 | $519 | $47 |
| Carvedilol | 49 | $466 | $10 |
| Isosorbide Mononitrate Er | 18 | $336 | $19 |
| Furosemide | 52 | $327 | $6 |
| Metoprolol | 27 | $249 | $9 |
| Hydralazine | 13 | $235 | $18 |
| Hydrochlorothiazide | 14 | $132 | $9 |
| Omeprazole | 11 | $83 | $8 |
2018: 15 drugs
| Xarelto | 47 | $24,926 | $530 |
| Brilinta | 38 | $16,405 | $432 |
| Eliquis | 25 | $6,892 | $276 |
| Metoprolol | 143 | $3,852 | $27 |
| Clopidogrel | 50 | $371 | $7 |
| Amlodipine Besylate | 49 | $280 | $6 |
| Lisinopril | 46 | $275 | $6 |
| Atorvastatin | 31 | $274 | $9 |
| Metoprolol | 32 | $173 | $5 |
| Pentoxifylline | 11 | $165 | $15 |
| Warfarin | 12 | $153 | $13 |
| Losartan | 27 | $135 | $5 |
| Isosorbide Mononitrate Er | 11 | $119 | $11 |
| Carvedilol | 23 | $116 | $5 |
| Furosemide | 40 | $116 | $3 |
2017: 11 drugs
| Brilinta | 14 | $4,685 | $335 |
| Metoprolol | 47 | $1,631 | $35 |
| Isosorbide Mononitrate Er | 26 | $421 | $16 |
| Atorvastatin | 37 | $412 | $11 |
| Clopidogrel | 42 | $387 | $9 |
| Nitroglycerin | 13 | $289 | $22 |
| Lisinopril | 30 | $178 | $6 |
| Carvedilol | 18 | $177 | $10 |
| Metoprolol | 25 | $95 | $4 |
| Amlodipine Besylate | 29 | $85 | $3 |
| Furosemide | 13 | $56 | $4 |
2016: 13 drugs
| Eliquis | 22 | $8,447 | $384 |
| Effient | 11 | $4,232 | $385 |
| Diltiazem 24hr Er | 12 | $1,795 | $150 |
| Metoprolol | 42 | $1,056 | $25 |
| Isosorbide Mononitrate Er | 25 | $340 | $14 |
| Clopidogrel | 43 | $272 | $6 |
| Atorvastatin | 32 | $233 | $7 |
| Metoprolol | 42 | $165 | $4 |
| Furosemide | 30 | $141 | $5 |
| Lisinopril | 35 | $135 | $4 |
| Warfarin | 13 | $111 | $9 |
| Carvedilol | 15 | $82 | $5 |
| Amlodipine Besylate | 17 | $72 | $4 |
2015: 1 drug
| Clopidogrel | 15 | $199 | $13 |
2014: 1 drug
| Clopidogrel | 13 | $131 | $10 |
Money from drug and device companies
$10,170 in 2025
| 2025 | 16 | 112 | None | $10,170 |
| 2024 | 19 | 102 | None | $3,831 |
| 2023 | 25 | 91 | None | $1,787 |
| 2022 | 17 | 133 | None | $5,945 |
| 2021 | 8 | 31 | None | $1,480 |
| 2020 | 13 | 18 | None | $430 |
| 2019 | 16 | 43 | None | $2,140 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Corevalve Evolut R | $5,465 | 37 payments
|
| Abbott Laboratories | Optis | $2,115 | 14 payments
|
| Shockwave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $759 | 16 payments
|
| Teleflex | Manta | $639 | 5 payments
|
| Edwards Lifesciences | Pascal | $247 | 2 payments
|
| Abiomed | None | $221 | 4 payments
|
See all 112 published payments
| Medtronic | Meals · 2025-12-16 | Symplicity G3 | $15 |
| Teleflex | Meals · 2025-12-11 | Manta | $92 |
| Teleflex | Meals · 2025-12-11 | Manta | $92 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-09 | Kerendia | $15 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-08 | Jardiance | $24 |
| Medtronic | Travel · 2025-12-05 | Corevalve Evolut R | $547 |
| Medtronic | Travel · 2025-12-05 | Corevalve Evolut R | $35 |
| Medtronic | Travel · 2025-12-05 | Corevalve Evolut R | $35 |
| Pfizer | Meals · 2025-12-03 | Eliquis | $29 |
| Abiomed | Meals · 2025-11-25 | None | $49 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-24 | Jardiance | $24 |
| Teleflex | Meals · 2025-11-12 | Manta | $183 |
| Medtronic | Meals · 2025-11-05 | Micra | $40 |
| Medtronic | Meals · 2025-10-30 | Corevalve Evolut R | $116 |
| Actelion Pharmaceuticals US | Meals · 2025-10-28 | Opsynvi | $24 |
| Edwards Lifesciences | Meals · 2025-10-26 | Pascal | $236 |
| Medtronic | Meals · 2025-10-25 | Symplicity G3 | $190 |
| Teleflex | Meals · 2025-10-23 | Guideliner | $73 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-14 | Kerendia | $22 |
| Abbott Laboratories | Meals · 2025-10-08 | Assurity | $9 |
| Teleflex | Meals · 2025-10-03 | Manta | $200 |
| Abiomed | Meals · 2025-10-02 | None | $104 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-22 | Kerendia | $18 |
| Novartis Pharmaceuticals | Meals · 2025-09-16 | Leqvio | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-06 | Farxiga | $19 |
| Abbott Laboratories | Meals · 2025-09-04 | Aveir | $156 |
| Actelion Pharmaceuticals US | Meals · 2025-09-02 | Opsynvi | $35 |
| Merck Sharp & Dohme | Meals · 2025-08-20 | Verquvo | $19 |
| Novartis Pharmaceuticals | Meals · 2025-08-19 | Leqvio | $11 |
| Novartis Pharmaceuticals | Meals · 2025-08-19 | Leqvio | $11 |
| Novartis Pharmaceuticals | Meals · 2025-08-04 | Leqvio | $27 |
| Abiomed | Meals · 2025-07-08 | None | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-27 | Farxiga | $14 |
| Shockwave Medical | Meals · 2025-06-25 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $7 |
| Novartis Pharmaceuticals | Meals · 2025-06-23 | Leqvio | $26 |
| Pfizer | Meals · 2025-06-23 | Eliquis | $29 |
| Medtronic | Travel · 2025-06-20 | None | $450 |
| Medtronic | Travel · 2025-06-20 | None | $299 |
| Medtronic | Travel · 2025-06-20 | None | $84 |
| Medtronic | Meals · 2025-06-20 | None | $91 |
| Medtronic | Meals · 2025-06-20 | None | $136 |
| Medtronic | Meals · 2025-06-20 | None | $63 |
| Medtronic | Meals · 2025-06-20 | Azure Xt Dr Mri Surescan | $140 |
| Shockwave Medical | Meals · 2025-06-17 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $20 |
| Medtronic | Meals · 2025-06-09 | Micra | $21 |
| Actelion Pharmaceuticals US | Meals · 2025-05-27 | Opsumit | $26 |
| Shockwave Medical | Meals · 2025-05-22 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $4 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-20 | Kerendia | $15 |
| Abbott Laboratories | Travel · 2025-05-19 | Optis | $504 |
| Abbott Laboratories | Travel · 2025-05-19 | Optis | $9 |
| Novartis Pharmaceuticals | Meals · 2025-05-13 | Leqvio | $10 |
| Edwards Lifesciences | Meals · 2025-05-13 | Pascal | $11 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-12 | Jardiance | $23 |
| Abbott Laboratories | Travel · 2025-05-06 | Optis | $337 |
| Abbott Laboratories | Travel · 2025-05-06 | Optis | $337 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-05 | Kerendia | $30 |
| Abbott Laboratories | Meals · 2025-04-30 | Optis | $135 |
| Abbott Laboratories | Meals · 2025-04-30 | Optis | $50 |
| Abbott Laboratories | Meals · 2025-04-30 | Optis | $107 |
| Abbott Laboratories | Meals · 2025-04-30 | Optis | $94 |
| Abbott Laboratories | Meals · 2025-04-30 | Optis | $162 |
| Abbott Laboratories | Meals · 2025-04-30 | Optis | $111 |
| Abbott Laboratories | Meals · 2025-04-30 | Optis | $93 |
| Medtronic | Meals · 2025-04-25 | Micra | $25 |
| Shockwave Medical | Meals · 2025-04-24 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $23 |
| Shockwave Medical | Meals · 2025-04-21 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $10 |
| Novartis Pharmaceuticals | Meals · 2025-04-16 | Leqvio | $19 |
| Abiomed | Meals · 2025-04-15 | None | $43 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-14 | Jardiance | $27 |
| Abbott Laboratories | Meals · 2025-04-14 | Unify Assura | $11 |
| Merck Sharp & Dohme | Meals · 2025-03-25 | Verquvo | $24 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-03-18 | Lifevest | $14 |
| Shockwave Medical | Meals · 2025-03-18 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $27 |
| Medtronic | Meals · 2025-03-18 | Micra | $14 |
| Shockwave Medical | Meals · 2025-03-12 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $11 |
| Pfizer | Meals · 2025-03-12 | Eliquis | $21 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-11 | Jardiance | $20 |
| Medtronic | Meals · 2025-03-04 | None | $6 |
| Medtronic | Meals · 2025-03-04 | Micra | $18 |
| Medtronic | Meals · 2025-02-21 | Micra | $37 |
| Novartis Pharmaceuticals | Meals · 2025-02-10 | Entresto | $25 |
| Shockwave Medical | Meals · 2025-02-07 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $50 |
| Shockwave Medical | Travel · 2025-02-07 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $330 |
| Shockwave Medical | Meals · 2025-02-07 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $49 |
| Shockwave Medical | Meals · 2025-02-07 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $161 |
| Medtronic | Meals · 2025-02-07 | Micra | $26 |
| Shockwave Medical | Meals · 2025-02-04 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $6 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-03 | Kerendia | $18 |
| Medtronic | Meals · 2025-02-02 | None | $151 |
| Medtronic | Meals · 2025-02-02 | None | $150 |
| Medtronic | Meals · 2025-02-02 | None | $71 |
| Medtronic | Meals · 2025-02-01 | Cobalt Dr Mri Surescan | $118 |
| Medtronic | Meals · 2025-02-01 | Cobalt Dr Mri Surescan | $148 |
| Medtronic | Meals · 2025-02-01 | None | $228 |
| Medtronic | Meals · 2025-02-01 | None | $163 |
| Medtronic | Meals · 2025-02-01 | None | $207 |
| Medtronic | Meals · 2025-02-01 | None | $156 |
| Medtronic | Travel · 2025-02-01 | None | $349 |
| Medtronic | Travel · 2025-02-01 | None | $78 |
| Shockwave Medical | Meals · 2025-01-31 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $23 |
| Medtronic | Travel · 2025-01-31 | None | $349 |
| Medtronic | Travel · 2025-01-31 | None | $76 |
| Medtronic | Meals · 2025-01-31 | None | $209 |
| Shockwave Medical | Meals · 2025-01-30 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $10 |
| Merck Sharp & Dohme | Meals · 2025-01-28 | Verquvo | $17 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-27 | Camzyos | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-21 | Jardiance | $18 |
| Medtronic | Travel · 2025-01-18 | None | $622 |
| Boston Scientific | Meals · 2025-01-16 | Watchman Flx | $32 |
| Medtronic | Meals · 2025-01-16 | Corevalve Evolut R | $4 |
| Shockwave Medical | Meals · 2025-01-08 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $19 |
| Shockwave Medical | Meals · 2025-01-07 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $9 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,831
| Abbott Laboratories | Aveir | $1,913 | 26 payments
|
| Medtronic | Micra | $377 | 17 payments
|
| Abiomed | Impella | $297 | 7 payments
|
| Novo Nordisk | Wegovy | $251 | 5 payments
|
| Novartis Pharmaceuticals | Entresto | $219 | 11 payments
|
| Merck Sharp & Dohme | Verquvo | $131 | 7 payments
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $100 | 3 payments
|
| Amgen | Repatha | $93 | 4 payments
|
| Pfizer | Eliquis | $74 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $62 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $62 | 2 payments
|
| Boston Scientific | Watchman Flx | $61 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $53 | 3 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $38 | 2 payments
|
| Lexicon Pharmaceuticals | None | $31 | 2 payments
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $27 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $16 | 1 payment
|
| Impulse Dynamics (USA) | Optimizer | $14 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $13 | 1 payment
|
2023: $1,787
| Boston Scientific | Wolverine Coronary Cutting Balloon | $344 | 22 payments
|
| Abbott Laboratories | Navitor | $215 | 5 payments
|
| Medtronic | Micra | $184 | 11 payments
|
| Novartis Pharmaceuticals | Leqvio | $170 | 8 payments
|
| Janssen Pharmaceuticals | Xarelto | $112 | 6 payments
|
| Amgen | Repatha | $94 | 5 payments
|
| Impulse Dynamics (USA) | Optimizer | $82 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $81 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $65 | 4 payments
|
| AngioDynamics | Alphavac | $51 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $48 | 3 payments
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $42 | 2 payments
|
| Merck Sharp & Dohme | Verquvo | $34 | 2 payments
|
| Lexicon Pharmaceuticals | Inpefa | $31 | 2 payments
|
| Tactile Systems Technology | Flexitouch Plus | $30 | 2 payments
|
| Pfizer | Eliquis | $28 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $27 | 1 payment
|
| Chiesi USA | Kengreal | $22 | 1 payment
|
| Novo Nordisk | Ozempic | $21 | 1 payment
|
| Cook Medical | Zilver Ptx | $19 | 1 payment
|
| Cardiovascular Systems | Diamondback Peripheral | $19 | 1 payment
|
| Abiomed | Impella | $18 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $18 | 1 payment
|
| Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor | $15 | 1 payment
|
| HeartFlow | Ffrct | $14 | 1 payment
|
2022: $5,945
| Medtronic | Advisa Dr Mri Surescan | $2,773 | 24 payments
|
| Abbott Laboratories | Assurity | $1,027 | 10 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $704 | 10 payments
|
| Boston Scientific | Jetstream Sc | $527 | 39 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $231 | 12 payments
|
| Shockwave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $130 | 8 payments
|
| Merck Sharp & Dohme | Verquvo | $119 | 6 payments
|
| Janssen Pharmaceuticals | Xarelto | $95 | 6 payments
|
| Novartis Pharmaceuticals | Entresto | $90 | 5 payments
|
| Sanofi-Aventis U.S. | Multaq | $55 | 3 payments
|
| Pfizer | Eliquis | $49 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $39 | 2 payments
|
| Amgen | Repatha | $31 | 2 payments
|
| Resmed | Air 11 | $25 | 1 payment
|
| Chiesi USA | Kengreal | $24 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $13 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Verquvo | $12 | 1 payment
|
2021: $1,480
| Abbott Laboratories | Assurity Pacemaker | $1,103 | 9 payments
|
| Janssen Pharmaceuticals | Xarelto | $138 | 7 payments
|
| Medtronic | Micra | $130 | 9 payments
|
| Kiniksa Pharmaceuticals | None | $44 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Verquvo | $19 | 1 payment
|
| Bard Peripheral Vascular | Lifestream | $16 | 1 payment
|
| Amgen | Repatha | $15 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $14 | 1 payment
|
2020: $430
| Janssen Pharmaceuticals | Xarelto | $87 | 5 payments
|
| Abbott Laboratories | Cardiomems Hf System | $82 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve | $60 | 1 payment
|
| Asahi Intecc USA | Asahi Ptca Guide Wire | $41 | 1 payment
|
| iRhythm Technologies | Zio Patch | $31 | 1 payment
|
| Cardiovascular Systems | Coronary Orbital Atherectomy System | $20 | 1 payment
|
| Boston Scientific | General - Structural Heart | $18 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $17 | 1 payment
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $16 | 1 payment
|
| Abiomed | Impella | $16 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $15 | 1 payment
|
| Amgen | Repatha | $14 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $13 | 1 payment
|
2019: $2,140
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve | $1,366 | 8 payments
|
| Abbott Laboratories | Cardiomems Hf System | $157 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $84 | 5 payments
|
| AngioDynamics | None | $69 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $69 | 4 payments
|
| Novartis Pharmaceuticals | Entresto | $69 | 4 payments
|
| Amgen | Repatha | $64 | 5 payments
|
| Sanofi-Aventis U.S. | Praluent | $46 | 2 payments
|
| Boston Scientific | General Tachy | $41 | 2 payments
|
| Medtronic Vascular | 3f | $41 | 2 payments
|
| Portola Pharmaceuticals | Andexxa | $30 | 1 payment
|
| Pfizer | Eliquis | $28 | 2 payments
|
| Osprey Medical | Dyevert | $27 | 1 payment
|
| Cardiovascular Systems | Peripheral Orbital Atherectomy System | $24 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $14 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $11 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 97.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1699969287
- Licence
- CA C150276, WA MD00047415, WV 22763California C150276: Current · expires 2028-11-30Washington MD.MD.00047415: Expired
- Group
- Adventist Health Physicians Network · Lodi Memorial Hospital Association Inc
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 1801 E March Ln Ste D400, Stockton, CA, 95210
- NPI first listed
- 2007-08-28
- NPI last updated
- 2020-03-02
- NPI record certified
- 2020-03-02
This is when the NPI record was last certified, not a medical board exam.